The rise and fall of pneumococcal serotypes carried in the PCV era

Vanessa Devine, David W Cleary, Johanna M C Jefferies, Rebecca Anderson, Denise Morris, Andrew C Tuck, Rebecca A Gladstone, Grace O' Doherty, Priya Kuruparan, Stephen D Bentley, Saul N Faust, Stuart C Clarke

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Streptococcus pneumoniae is a major cause of meningitis, sepsis and pneumonia worldwide. Vaccination using pneumococcal conjugate vaccines (PCV) has therefore been part of the UK's childhood immunisation programme since 2006. Here we describe pneumococcal carriage rates in children under five years of age attending the paediatric department of a large UK hospital in response to vaccine implementation over seven winter seasons from 2006 to 2013. S. pneumoniae (n=696) were isolated from nasopharyngeal swabs (n=2267) collected during seven consecutive winters, October to March, 2006/7 to 2012/13. This includes the period immediately following the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2006 in addition to pre- and post-PCV13 introduction in 2010. We show a decrease in PCV13 vaccine serotypes (VT) in the three years following PCV13 vaccine implementation (2010/11 to 2012/13). Serotype 6A represented the only observed VT following PCV13 implementation with all others (including PCV7 serotypes) absent from carriage. Overall pneumococcal carriage, attributable to non-VT (NVT), was consistent across all sampling years with a mean of 31·1%. The ten most frequently isolated NVTs were 6C, 11A, 15B, 23B, 15A, 21, 22F, 35F, 23A and 15C. Fluctuations in the prevalence of each were however noted. Comparing prevalence at 2006/07 with 2012/13 only 15A was shown to have increased significantly (p value of 0·003) during the course of PCV implementation. These data support the increasing evidence that the primary effect of PCVs is due to population immunity by reducing or eliminating the carriage of invasive VT serotypes. With IPD being increasingly attributed to non-vaccine serotypes, surveillance of carriage data continues to act as an early warning system for vaccine design and public health policy that require continual data of both carried pneumococcal serotypes and IPD attributed serotype data.
LanguageEnglish
Article numberVolume 35, Issue 9
Pages1293-1298
Number of pages6
JournalVaccine
Volume35
Issue number9
Publication statusPublished - 1 Mar 2017

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Streptococcus pneumoniae
Vaccines
Immunization Programs
Public Policy
Health Policy
Serogroup
Meningitis
Immunity
Sepsis
Pneumonia
Vaccination
Public Health
Pediatrics
Population

Cite this

Devine, V., Cleary, D. W., Jefferies, J. M. C., Anderson, R., Morris, D., Tuck, A. C., ... Clarke, S. C. (2017). The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine, 35(9), 1293-1298. [Volume 35, Issue 9].
Devine, Vanessa ; Cleary, David W ; Jefferies, Johanna M C ; Anderson, Rebecca ; Morris, Denise ; Tuck, Andrew C ; Gladstone, Rebecca A ; O' Doherty, Grace ; Kuruparan, Priya ; Bentley, Stephen D ; Faust, Saul N ; Clarke, Stuart C. / The rise and fall of pneumococcal serotypes carried in the PCV era. In: Vaccine. 2017 ; Vol. 35, No. 9. pp. 1293-1298.
@article{2483989a82ce4799ad74177675aca083,
title = "The rise and fall of pneumococcal serotypes carried in the PCV era",
abstract = "Streptococcus pneumoniae is a major cause of meningitis, sepsis and pneumonia worldwide. Vaccination using pneumococcal conjugate vaccines (PCV) has therefore been part of the UK's childhood immunisation programme since 2006. Here we describe pneumococcal carriage rates in children under five years of age attending the paediatric department of a large UK hospital in response to vaccine implementation over seven winter seasons from 2006 to 2013. S. pneumoniae (n=696) were isolated from nasopharyngeal swabs (n=2267) collected during seven consecutive winters, October to March, 2006/7 to 2012/13. This includes the period immediately following the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2006 in addition to pre- and post-PCV13 introduction in 2010. We show a decrease in PCV13 vaccine serotypes (VT) in the three years following PCV13 vaccine implementation (2010/11 to 2012/13). Serotype 6A represented the only observed VT following PCV13 implementation with all others (including PCV7 serotypes) absent from carriage. Overall pneumococcal carriage, attributable to non-VT (NVT), was consistent across all sampling years with a mean of 31·1{\%}. The ten most frequently isolated NVTs were 6C, 11A, 15B, 23B, 15A, 21, 22F, 35F, 23A and 15C. Fluctuations in the prevalence of each were however noted. Comparing prevalence at 2006/07 with 2012/13 only 15A was shown to have increased significantly (p value of 0·003) during the course of PCV implementation. These data support the increasing evidence that the primary effect of PCVs is due to population immunity by reducing or eliminating the carriage of invasive VT serotypes. With IPD being increasingly attributed to non-vaccine serotypes, surveillance of carriage data continues to act as an early warning system for vaccine design and public health policy that require continual data of both carried pneumococcal serotypes and IPD attributed serotype data.",
author = "Vanessa Devine and Cleary, {David W} and Jefferies, {Johanna M C} and Rebecca Anderson and Denise Morris and Tuck, {Andrew C} and Gladstone, {Rebecca A} and {O' Doherty}, Grace and Priya Kuruparan and Bentley, {Stephen D} and Faust, {Saul N} and Clarke, {Stuart C}",
year = "2017",
month = "3",
day = "1",
language = "English",
volume = "35",
pages = "1293--1298",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "9",

}

Devine, V, Cleary, DW, Jefferies, JMC, Anderson, R, Morris, D, Tuck, AC, Gladstone, RA, O' Doherty, G, Kuruparan, P, Bentley, SD, Faust, SN & Clarke, SC 2017, 'The rise and fall of pneumococcal serotypes carried in the PCV era', Vaccine, vol. 35, no. 9, Volume 35, Issue 9, pp. 1293-1298.

The rise and fall of pneumococcal serotypes carried in the PCV era. / Devine, Vanessa; Cleary, David W; Jefferies, Johanna M C; Anderson, Rebecca; Morris, Denise; Tuck, Andrew C; Gladstone, Rebecca A; O' Doherty, Grace; Kuruparan, Priya; Bentley, Stephen D; Faust, Saul N; Clarke, Stuart C.

In: Vaccine, Vol. 35, No. 9, Volume 35, Issue 9, 01.03.2017, p. 1293-1298.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The rise and fall of pneumococcal serotypes carried in the PCV era

AU - Devine, Vanessa

AU - Cleary, David W

AU - Jefferies, Johanna M C

AU - Anderson, Rebecca

AU - Morris, Denise

AU - Tuck, Andrew C

AU - Gladstone, Rebecca A

AU - O' Doherty, Grace

AU - Kuruparan, Priya

AU - Bentley, Stephen D

AU - Faust, Saul N

AU - Clarke, Stuart C

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Streptococcus pneumoniae is a major cause of meningitis, sepsis and pneumonia worldwide. Vaccination using pneumococcal conjugate vaccines (PCV) has therefore been part of the UK's childhood immunisation programme since 2006. Here we describe pneumococcal carriage rates in children under five years of age attending the paediatric department of a large UK hospital in response to vaccine implementation over seven winter seasons from 2006 to 2013. S. pneumoniae (n=696) were isolated from nasopharyngeal swabs (n=2267) collected during seven consecutive winters, October to March, 2006/7 to 2012/13. This includes the period immediately following the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2006 in addition to pre- and post-PCV13 introduction in 2010. We show a decrease in PCV13 vaccine serotypes (VT) in the three years following PCV13 vaccine implementation (2010/11 to 2012/13). Serotype 6A represented the only observed VT following PCV13 implementation with all others (including PCV7 serotypes) absent from carriage. Overall pneumococcal carriage, attributable to non-VT (NVT), was consistent across all sampling years with a mean of 31·1%. The ten most frequently isolated NVTs were 6C, 11A, 15B, 23B, 15A, 21, 22F, 35F, 23A and 15C. Fluctuations in the prevalence of each were however noted. Comparing prevalence at 2006/07 with 2012/13 only 15A was shown to have increased significantly (p value of 0·003) during the course of PCV implementation. These data support the increasing evidence that the primary effect of PCVs is due to population immunity by reducing or eliminating the carriage of invasive VT serotypes. With IPD being increasingly attributed to non-vaccine serotypes, surveillance of carriage data continues to act as an early warning system for vaccine design and public health policy that require continual data of both carried pneumococcal serotypes and IPD attributed serotype data.

AB - Streptococcus pneumoniae is a major cause of meningitis, sepsis and pneumonia worldwide. Vaccination using pneumococcal conjugate vaccines (PCV) has therefore been part of the UK's childhood immunisation programme since 2006. Here we describe pneumococcal carriage rates in children under five years of age attending the paediatric department of a large UK hospital in response to vaccine implementation over seven winter seasons from 2006 to 2013. S. pneumoniae (n=696) were isolated from nasopharyngeal swabs (n=2267) collected during seven consecutive winters, October to March, 2006/7 to 2012/13. This includes the period immediately following the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2006 in addition to pre- and post-PCV13 introduction in 2010. We show a decrease in PCV13 vaccine serotypes (VT) in the three years following PCV13 vaccine implementation (2010/11 to 2012/13). Serotype 6A represented the only observed VT following PCV13 implementation with all others (including PCV7 serotypes) absent from carriage. Overall pneumococcal carriage, attributable to non-VT (NVT), was consistent across all sampling years with a mean of 31·1%. The ten most frequently isolated NVTs were 6C, 11A, 15B, 23B, 15A, 21, 22F, 35F, 23A and 15C. Fluctuations in the prevalence of each were however noted. Comparing prevalence at 2006/07 with 2012/13 only 15A was shown to have increased significantly (p value of 0·003) during the course of PCV implementation. These data support the increasing evidence that the primary effect of PCVs is due to population immunity by reducing or eliminating the carriage of invasive VT serotypes. With IPD being increasingly attributed to non-vaccine serotypes, surveillance of carriage data continues to act as an early warning system for vaccine design and public health policy that require continual data of both carried pneumococcal serotypes and IPD attributed serotype data.

M3 - Article

VL - 35

SP - 1293

EP - 1298

JO - Vaccine

T2 - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 9

M1 - Volume 35, Issue 9

ER -

Devine V, Cleary DW, Jefferies JMC, Anderson R, Morris D, Tuck AC et al. The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine. 2017 Mar 1;35(9):1293-1298. Volume 35, Issue 9.